Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Sees Significant Drop in Short Interest

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) was the target of a large decrease in short interest in December. As of December 31st, there was short interest totalling 1,030,000 shares, a decrease of 14.2% from the December 15th total of 1,200,000 shares. Approximately 1.8% of the shares of the stock are short sold. Based on an average daily volume of 131,000 shares, the short-interest ratio is currently 7.9 days.

Nautilus Biotechnology Stock Down 2.1 %

Shares of NAUT stock traded down $0.04 on Thursday, reaching $1.90. The company’s stock had a trading volume of 68,207 shares, compared to its average volume of 139,801. The company has a market capitalization of $238.56 million, a P/E ratio of -3.39 and a beta of 1.20. Nautilus Biotechnology has a 12-month low of $1.61 and a 12-month high of $3.12. The stock’s 50 day simple moving average is $2.05 and its 200-day simple moving average is $2.43.

Nautilus Biotechnology (NASDAQ:NAUT) last released its quarterly earnings results on Tuesday, October 29th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.04. During the same period in the previous year, the firm posted ($0.13) earnings per share. Research analysts expect that Nautilus Biotechnology will post -0.57 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group downgraded shares of Nautilus Biotechnology from a “neutral” rating to a “sell” rating and lowered their price target for the stock from $2.25 to $1.75 in a report on Thursday, December 5th.

Institutional Investors Weigh In On Nautilus Biotechnology

Hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC bought a new position in shares of Nautilus Biotechnology in the 3rd quarter worth $50,000. The Manufacturers Life Insurance Company purchased a new position in Nautilus Biotechnology in the third quarter worth $67,000. China Universal Asset Management Co. Ltd. grew its position in Nautilus Biotechnology by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 24,121 shares of the company’s stock worth $69,000 after acquiring an additional 9,404 shares in the last quarter. MetLife Investment Management LLC bought a new position in Nautilus Biotechnology in the third quarter valued at $87,000. Finally, Barclays PLC raised its position in Nautilus Biotechnology by 79.6% during the third quarter. Barclays PLC now owns 106,174 shares of the company’s stock valued at $303,000 after purchasing an additional 47,059 shares in the last quarter. 50.71% of the stock is currently owned by institutional investors.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.